Nerve stimulation procedure can improve bowel control problems

By Amanda Harper

An estimated 18 million adults suffer silently with a life-altering condition, known as bowel incontinence, because they believe the problem can’t be fixed.

But problems with are common, says Ian Paquette, MD—especially among women who’ve labored through multiple childbirths that resulted in obstetric injuries to the rectum. 

The U.S. Food and Drug Administration recently approved a new procedure known as sacral (marketed by Medtronic as InterStim Therapy) for the treatment of bowel incontinence. Paquette is the first colon and rectal surgeon in the Greater Cincinnati region to offer sacral nerve stimulation for bowel incontinence.

"Problems with bowel control most often occur in women who’ve had children because the physical stress of labor weakens the pelvic floor muscles—particularly if the sphincter muscle was injured,” explains Paquette, a UC Health colon and rectal surgeon and assistant professor of surgery at the UC College of Medicine. "If that muscle tear doesn’t fully heal, over time it becomes weaker and the patient experiences problems with bowel control—sometimes these symptoms may occur many years later.”  

Sacral nerve stimulation involves implantation of a small device next to the sacral nerve that acts as a type of pacemaker, helping to control the timing and frequency of bowel movements. The same device has been used in the United States for 10 years to treat overactive bladder and urinary incontinence.

A multicenter clinical trial sponsored by Medtronic showed that 47 percent of people who had sacral nerve stimulation achieved 100 percent bowel continence, which lasted at least three years. Additionally, 86 percent of the people improved at least 50 percent.

"The great thing about this procedure is that the patient has the opportunity to live with the device for two weeks during a test phase and see if it helps their bowel control before choosing to undergo the device implantation,” adds Paquette.  

During this test phase, a flexible wire is implanted near the patient’s tailbone and connected to a small external device worn on the patient’s waistband. The external device sends mild electric pulses through the wire to stimulate nerves near the tailbone and regularize bowel activities. If the device has positive results during the test phase, the patient can choose to have the device permanently implanted through minimally invasive surgery. 

Before pursuing sacral nerve stimulation, Paquette completes a comprehensive patient evaluation to identify the underlying causes of incontinence. This includes assessing nerve and voiding function as well as anal sphincter muscle strength and integrity. It is important for the patient to see a specialist who commonly deals with this disorder to determine the exact cause of the condition, and to discuss alternate surgical and nonsurgical approaches.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Sierra Leone streets deserted as shutdown begins

3 hours ago

Sierra Leone's normally chaotic capital resembled a ghost town on Friday as residents were confined to their homes for the start of a three-day lockdown aimed at halting the deadly Ebola epidemic.

Sierra Leone launches controversial Ebola shutdown

4 hours ago

Sierra Leone on Friday launched a controversial three-day shutdown to contain the deadly spread of the Ebola virus, as the UN Security Council declared the deadly outbreak a threat to world peace.

Cooling of dialysis fluids protects against brain damage

17 hours ago

While dialysis can cause blood pressure changes that damage the brain, cooling dialysis fluids can protect against such effects. The findings come from a study appearing in an upcoming issue of the Journal of the American So ...

Two Ebola vaccines to be tested in Switzerland

18 hours ago

Clinical trials of two experimental vaccines against the deadly Ebola virus are due to begin soon in Switzerland, the country's Tropical and Public Health Institute said on Thursday.

User comments